Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. (Q46699863)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maria Gabriella Ferrandina

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Giovanni Scambia

6

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Giacomo Corrado

3

object named as

Giacomo Corrado

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Manuela Ludovisi

2

object named as

Manuela Ludovisi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Vito Carone

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Marco Petrillo

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

0 references

publication date

17 March 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

109

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

187-193

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Tumor markers in the management of patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

On the relationship between response to treatment and survival time

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.039

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.01.039

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18343487%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46699863&oldid=2032981591"